Information Provided By:
Fly News Breaks for December 23, 2019
KPTI
Dec 23, 2019 | 10:34 EDT
After Karyopharm announced this morning that it submitted an NDA to the FDA for accelerated approval for Xpovio in patients with relapsed or refractory diffuse large B-Cell lymphoma, H.C. Wainwright analyst Edward White said he expects Xpovio could receive approval and sees a launch in 2021, adding that he estimates sales of $241.2M in 2026 for the DLBCL indication. White keeps a Buy rating and $36 price target on Karyopharm shares.
News For KPTI From the Last 2 Days
There are no results for your query KPTI
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.